Brain metastases trial: can adding radiation boost immunotherapy?
NCT ID NCT03340129
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is for people with stage IV melanoma that has spread to the brain. It compares two treatments: a combination of two immunotherapy drugs (ipilimumab and nivolumab) alone, or the same drugs plus precise, targeted radiation to the brain tumors. The goal is to see if adding radiation helps control the disease and reduces the chance of dying from neurological causes. About 218 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ipilimumab (Yervoy) and nivolumab (Opdivo) with or without stereotactic radiotherapy
What this could lead to
If it works, this could show that adding precise radiation to immunotherapy helps control melanoma brain metastases better than immunotherapy alone.
What could go wrong
This is a phase 2 trial, so results are still early. The combination may cause more side effects, and it's unclear if it will improve survival or just delay progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alfred Hospital
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact
-
Calvary Mater NewcastleHospital
RECRUITINGWaratah, New South Wales, 2298, Australia
Contact
-
Melanoma Institute Australia
RECRUITINGWollstonecraft, New South Wales, 2065, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oslo Univesity Hospital Radiumhospitalet
TERMINATEDOslo, Oslo, 0379, Norway
-
Peter MacCallum Cancer Centre
RECRUITINGEast Melbourne, Victoria, 3002, Australia
Contact
-
Princess Alexandra Hospital
RECRUITINGWoolloongabba, Queensland, 4102, Australia
Contact
-
Royal Adelaide Hospital
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact
-
Sir Charles Gairdner Hosptial
RECRUITINGPerth, Western Australia, 6009, Australia
Contact
-
Westmead Hospital
RECRUITINGSydney, New South Wales, 2145, Australia
Contact
Contact